Vor Biopharma (NASDAQ:VOR) Shares Up 6.2% – Still a Buy?

Vor Biopharma Inc. (NASDAQ:VOR) traded up 6.2% on Wednesday . The stock traded as high as $24.01 and last traded at $24.04. Approximately 79,561 shares were traded during mid-day trading, a decline of 92% from the average session volume of 1,036,914 shares. The stock had previously closed at $22.64.

Wall Street Analysts Forecast Growth

VOR has been the topic of a number of recent research reports. Weiss Ratings raised shares of Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th. HC Wainwright reiterated a “buy” rating and set a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. Wall Street Zen raised Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Wedbush raised their price target on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.38.

Vor Biopharma Trading Up 5.8%

The company’s 50-day moving average price is $20.71 and its 200-day moving average price is $16.85.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). On average, research analysts expect that Vor Biopharma Inc. will post -2.56 EPS for the current fiscal year.

Institutional Trading of Vor Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its holdings in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Vor Biopharma during the first quarter worth about $140,000. XTX Topco Ltd bought a new position in shares of Vor Biopharma during the second quarter worth about $66,000. BNP Paribas Financial Markets raised its position in Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after buying an additional 5,058 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Vor Biopharma in the 3rd quarter valued at approximately $230,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).